Viyash Scientific has posted a very strong set of numbers for the first quarter of FY27. The company saw a sharp rise in profit, better margins and healthy revenue growth. Its net profit rose 114.9% year on year to ₹793 million. Revenue also rose 19.5% to ₹9,464 million.
The result is notable because profit grew much faster than revenue. This shows that the company did more than just sell more products. It also saw a clear rise in its operating profit and margins. EBITDA rose 59.2% to ₹2,047 million. EBITDA margin reached 21.6%, up from 16.2% in Q1 FY26.
The numbers point to a major rise in business efficiency. Viyash Scientific also has a very low net debt to EBITDA ratio of 0.1x. This gives the company a strong balance sheet as it seeks more growth through its own business as well as new deals.
Revenue Rises 19.5%
Revenue stood at ₹9,464 million in Q1 FY27. That was 19.5% higher than the ₹7,916 million figure from Q1 FY26.
A rise of close to 20% in revenue is a healthy result for a pharma company. More important is the fact that profit rose at a much faster rate. This gap between sales growth and profit growth shows that Viyash Scientific had a better cost structure and a stronger product mix during the quarter.
The company has a wide business base across pharma products, animal health and contract development and manufacturing. Its global reach also gives it access to several markets.
Viyash Scientific says it serves more than 150 countries and has 16 manufacturing sites. It also has 10 USFDA-approved units. This global base gives the company scope to expand its business without a full dependence on one market.
EBITDA Jumps 59.2%
The most important part of the Q1 result may be the EBITDA number.
EBITDA stood at ₹2,047 million, up 59.2% from ₹1,286 million in Q1 FY26. The EBITDA margin rose to 21.6% from 16.2%. That is an increase of 540 basis points.
A margin rise of 540 basis points in one year is significant. It means Viyash Scientific kept a much larger share of its revenue as operating profit.
The result also suggests that the company has more room to turn sales into profit. If this margin level stays close to 21.6% in the next few quarters, even a moderate rise in revenue could lead to a much larger rise in EBITDA.
This is why investors may focus on the margin more than the headline 115% profit rise. A one-quarter jump in profit can come from several factors, but a sustained rise in operating margin can have a much bigger effect on the long-term value of a business.
Net Profit More Than Doubles
Viyash Scientific reported PAT of ₹793 million for Q1 FY27. That marks a 114.9% rise from the same quarter last year.
In simple terms, the company made more than twice the profit it made a year ago. The profit rise was much faster than the 19.5% revenue rise.
This difference is important. A company can grow sales without a major rise in profit if costs rise at the same pace. Viyash Scientific had a different result in Q1 FY27. Its revenue rose by less than 20%, while EBITDA rose by more than 59% and PAT rose by almost 115%.
The figures show that the company entered FY27 with a much better profit profile than it had a year ago. Its FY26 results had already shown a major recovery, with full-year EBITDA up 59.6% and PAT up 1,324%.
Italy Deal Adds a New Growth Route
Apart from the quarterly numbers, Viyash Scientific also has a major international deal on its plate.
The company has signed a definitive agreement to acquire 100% of BioForLife Italia s.r.l. through its Alivira Animal Health business. The deal value is about EUR 16.98 million.
BioForLife Italia is based in Milan and operates in the animal health space. The target had sales of about EUR 9.0 million in calendar year 2025. It also has access to about 80% of Italian veterinary clinics.
This deal can give Viyash Scientific a direct commercial base in Italy. It can also help the company take more animal health products to the European market.
The deal is not just about adding one more company to the group. It can give Viyash Scientific a local platform, a customer base and a stronger position in the companion animal market.
Why the Italy Deal Matters
Europe is an important market for animal health products. A local presence can make it easier for Viyash Scientific to work with vets, distributors and other customers.
The BioForLife deal also fits with the company’s larger plan to build its animal health business. If the acquired business grows well, Viyash Scientific may gain more sales from Europe over time.
There is also a financial point to note. The deal has a deferred payment of EUR 1.98 million that is linked to milestones. This structure can reduce some of the risk that comes with an acquisition.
Still, the deal will need proper execution. The value of an acquisition depends not only on the purchase price but also on how well the buyer combines the new business with its own operations.
Balance Sheet Gives More Comfort
Another positive point is Viyash Scientific’s low net debt to EBITDA ratio of 0.1x.
This is a very low level of leverage. In simple terms, the company does not carry a large debt burden compared with its operating profit.
A strong balance sheet gives the company more freedom. It can support business expansion, product launches and acquisitions without placing too much pressure on its finances.
This is especially useful for a company with an international growth plan. New markets often need funds for sales teams, approvals, product launches and local operations. Low debt can make such plans easier to manage.
What Investors Should Watch Next
The Q1 FY27 numbers are clearly positive, but one quarter alone cannot prove that the same pace will continue.
The main factor to watch is the EBITDA margin. The rise from 16.2% to 21.6% is impressive. Investors will want to see whether Viyash Scientific can hold a similar level in later quarters.
Revenue growth also needs close attention. A 19.5% rise is healthy, but the company will need steady sales growth to support a long-term rise in profit.
The Italy acquisition is another key factor. Investors will want more details on the deal’s revenue contribution, costs, integration plans and future profit potential.
Management commentary can provide useful clues on these areas. Viyash Scientific had its Q1 FY27 earnings call scheduled for August 12, 2026, at 3:30 PM IST.
A Strong Start, But More Proof Is Needed
Viyash Scientific has started FY27 with a very strong quarter. Revenue rose 19.5% to ₹9,464 million, EBITDA rose 59.2% to ₹2,047 million and PAT rose 114.9% to ₹793 million. EBITDA margin rose to 21.6% from 16.2%, a gain of 540 basis points. Net debt to EBITDA stood at just 0.1x.
The Italy deal adds another important part to the story. The EUR 16.98 million BioForLife Italia acquisition can give the company a stronger base in the European animal health market.
The next step is simple: Viyash Scientific must prove that the Q1 margin and profit gains can last. If revenue growth stays healthy and the company keeps its margin near the Q1 level, the FY27 story could become much more interesting.
For now, the numbers show a company with faster profit growth, better margins, low debt and a clear push toward global expansion. That makes the Q1 FY27 result a quarter worth close attention from investors.
ALSO READ: Aviva Industries Q1 FY27 Profit Drops 35% Amid Audit Gaps
